title: Pharmacological modulation of human gastric volumes demonstrated noninvasively using SPECT imaging.
abstract: Three-dimensional single-photon emission computed tomography (SPECT) imaging allows noninvasive measurement of human postprandial gastric accommodation. The aim of this study was to determine whether 99mTCO4-SPECT demonstrates effects on pre- and postprandial gastric volumes of intravenous (i.v.) erythromycin lactobionate and sublingual isosorbide dinitrate, as predicted from previous literature. Twenty volunteers received no medication (controls), while 12 were randomized to either i.v. erythromycin 2 mg kg-1 over 20 min, or 10 mg sublingual isosorbide. After a 10-min preprandial SPECT measurement, a standard 300-mL, 300-kcal liquid meal was ingested, followed by a 20-min postprandial measurement. Gastric images were reconstructed from transaxial images and total volume was measured using the Analyseeth software system. Fasting gastric volume was greater with isosorbide [223 +/- 14 (SE) mL vs. 174 +/- 9 mL, control; P < 0.05], and postprandial volume was lower with erythromycin [393 +/- 27 mL vs. 582 +/- 17 mL, control; P < 0.05]. The ratio of postprandial over fasting volume and mean difference between pre- and postprandial volumes were significantly lower in both drug groups compared to controls. We conclude that 99mTCO4-SPECT imaging is able to semiquantitatively demonstrate pharmacological modulation of fasting gastric volume and postprandial accommodation in humans.
authors.affiliation: Enteric Neuroscience Program, Gastroenterology Research Unit, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
authors.forename: S S
authors.initials: SS
authors.lastname: Liau
authors.forename: M
authors.initials: M
authors.lastname: Camilleri
authors.forename: D Y
authors.initials: DY
authors.lastname: Kim
authors.forename: D
authors.initials: D
authors.lastname: Stephens
authors.forename: D D
authors.initials: DD
authors.lastname: Burton
authors.forename: M K
authors.initials: MK
authors.lastname: O'Connor
mesh_terms: D000286:Administration, Sublingual; D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000494:pharmacology; D004917:Erythromycin / Q000009:adverse effects / Q000494:pharmacology; D005215:Fasting / Q000502:physiology; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007548:Isosorbide Dinitrate / Q000009:adverse effects / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D019518:Postprandial Period / Q000502:physiology; D019275:Radiopharmaceuticals; D013670:Sodium Pertechnetate Tc 99m; D013270:Stomach / Q000000981:diagnostic imaging / Q000187:drug effects*; D015899:Tomography, Emission-Computed, Single-Photon; D014665:Vasodilator Agents / Q000009:adverse effects / Q000494:pharmacology
chemical_list: D000900:Anti-Bacterial Agents; D019275:Radiopharmaceuticals; D014665:Vasodilator Agents; D004917:Erythromycin; D013670:Sodium Pertechnetate Tc 99m; D007548:Isosorbide Dinitrate